Endoscopic ultrasound prediction of survival in pancreatic cancer

B. R. Stotland, G. G. Ginsberg, Douglas Orrick Faigel, D. Smith, M. L. Kochman

Research output: Contribution to journalArticle

Abstract

Endoscopic ultrasound (EUS) has been shown to be the most accurate imaging modality for preoperative T- and N-staging in pancreatic cancer. Pancreatic cancer (PanCa) often presents at an advanced stage, but a subset of patients may be cured by surgery. We prospectively followed patients after EUS for PanCa staging to determine the utility of EUS in predicting survival. Methods: 150 consecutive patients who underwent EUS (Olympus GF-UM20) for PanCa over a 42 month period were reviewed. Survival data was obtained on 93 patients. Results: All patients with T1 lesions (13) were alive at the time of this study. Results for all other lesions are presented below. For those with complete surgical pathologic staging, EUS had a 76% T-stage accuracy and a 66% N-stage accuracy. There was a trend towards improved survival for T2 versus T3 lesions at 15 months (27% for T2, 18% for T3) and 18 months (27% for T2, 9.5% for T3) (p<0.18). There was no trend towards improved survival for NO versus N1 lesions nor for those who underwent Whipple resection versus those who did not. Survival in months by EUS T- and N-staging # Alive 3 mo 6 mo 9 mo 12 mo 15 mo 18 mo T2 30/34 12/22 8/21 6/19 4/15 3/11 T3 40/47 21/40 16/39 8/29 4/22 2/21 NO 25/30 11/23 9/23 8/22 4/16 3/16 N1 45/50 22/39 15/37 6/26 4/21 2/16 Total 70/80 33/62 24/60 14/38 8/37 5/32 Conclusions: 1. EUS had a 77% T-stage accuracy. 2. EUS T-staging may predict long-term survival in pancreatic cancer. With a greater duration of follow-up for our cohort, we expect differences in survival between EUS T-staged pancreatic cancers to become significant. 3. EUS N-staging is not highly accurate (66% in this study), and does not predict long-term survival in this cohort of T-2 and T-3 lesions. 4. A substantial subset of patients (16%) live beyond 1.5 years after the diagnosis of pancreatic cancer regardless of whether a Whipple resection was performed.

Original languageEnglish (US)
JournalGastrointestinal Endoscopy
Volume45
Issue number4
StatePublished - 1997
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Survival
Time and Motion Studies
Neoplasm Staging

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Stotland, B. R., Ginsberg, G. G., Faigel, D. O., Smith, D., & Kochman, M. L. (1997). Endoscopic ultrasound prediction of survival in pancreatic cancer. Gastrointestinal Endoscopy, 45(4).

Endoscopic ultrasound prediction of survival in pancreatic cancer. / Stotland, B. R.; Ginsberg, G. G.; Faigel, Douglas Orrick; Smith, D.; Kochman, M. L.

In: Gastrointestinal Endoscopy, Vol. 45, No. 4, 1997.

Research output: Contribution to journalArticle

Stotland, BR, Ginsberg, GG, Faigel, DO, Smith, D & Kochman, ML 1997, 'Endoscopic ultrasound prediction of survival in pancreatic cancer', Gastrointestinal Endoscopy, vol. 45, no. 4.
Stotland, B. R. ; Ginsberg, G. G. ; Faigel, Douglas Orrick ; Smith, D. ; Kochman, M. L. / Endoscopic ultrasound prediction of survival in pancreatic cancer. In: Gastrointestinal Endoscopy. 1997 ; Vol. 45, No. 4.
@article{9c530802092c46c7a8794c8110fa6f0b,
title = "Endoscopic ultrasound prediction of survival in pancreatic cancer",
abstract = "Endoscopic ultrasound (EUS) has been shown to be the most accurate imaging modality for preoperative T- and N-staging in pancreatic cancer. Pancreatic cancer (PanCa) often presents at an advanced stage, but a subset of patients may be cured by surgery. We prospectively followed patients after EUS for PanCa staging to determine the utility of EUS in predicting survival. Methods: 150 consecutive patients who underwent EUS (Olympus GF-UM20) for PanCa over a 42 month period were reviewed. Survival data was obtained on 93 patients. Results: All patients with T1 lesions (13) were alive at the time of this study. Results for all other lesions are presented below. For those with complete surgical pathologic staging, EUS had a 76{\%} T-stage accuracy and a 66{\%} N-stage accuracy. There was a trend towards improved survival for T2 versus T3 lesions at 15 months (27{\%} for T2, 18{\%} for T3) and 18 months (27{\%} for T2, 9.5{\%} for T3) (p<0.18). There was no trend towards improved survival for NO versus N1 lesions nor for those who underwent Whipple resection versus those who did not. Survival in months by EUS T- and N-staging # Alive 3 mo 6 mo 9 mo 12 mo 15 mo 18 mo T2 30/34 12/22 8/21 6/19 4/15 3/11 T3 40/47 21/40 16/39 8/29 4/22 2/21 NO 25/30 11/23 9/23 8/22 4/16 3/16 N1 45/50 22/39 15/37 6/26 4/21 2/16 Total 70/80 33/62 24/60 14/38 8/37 5/32 Conclusions: 1. EUS had a 77{\%} T-stage accuracy. 2. EUS T-staging may predict long-term survival in pancreatic cancer. With a greater duration of follow-up for our cohort, we expect differences in survival between EUS T-staged pancreatic cancers to become significant. 3. EUS N-staging is not highly accurate (66{\%} in this study), and does not predict long-term survival in this cohort of T-2 and T-3 lesions. 4. A substantial subset of patients (16{\%}) live beyond 1.5 years after the diagnosis of pancreatic cancer regardless of whether a Whipple resection was performed.",
author = "Stotland, {B. R.} and Ginsberg, {G. G.} and Faigel, {Douglas Orrick} and D. Smith and Kochman, {M. L.}",
year = "1997",
language = "English (US)",
volume = "45",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Endoscopic ultrasound prediction of survival in pancreatic cancer

AU - Stotland, B. R.

AU - Ginsberg, G. G.

AU - Faigel, Douglas Orrick

AU - Smith, D.

AU - Kochman, M. L.

PY - 1997

Y1 - 1997

N2 - Endoscopic ultrasound (EUS) has been shown to be the most accurate imaging modality for preoperative T- and N-staging in pancreatic cancer. Pancreatic cancer (PanCa) often presents at an advanced stage, but a subset of patients may be cured by surgery. We prospectively followed patients after EUS for PanCa staging to determine the utility of EUS in predicting survival. Methods: 150 consecutive patients who underwent EUS (Olympus GF-UM20) for PanCa over a 42 month period were reviewed. Survival data was obtained on 93 patients. Results: All patients with T1 lesions (13) were alive at the time of this study. Results for all other lesions are presented below. For those with complete surgical pathologic staging, EUS had a 76% T-stage accuracy and a 66% N-stage accuracy. There was a trend towards improved survival for T2 versus T3 lesions at 15 months (27% for T2, 18% for T3) and 18 months (27% for T2, 9.5% for T3) (p<0.18). There was no trend towards improved survival for NO versus N1 lesions nor for those who underwent Whipple resection versus those who did not. Survival in months by EUS T- and N-staging # Alive 3 mo 6 mo 9 mo 12 mo 15 mo 18 mo T2 30/34 12/22 8/21 6/19 4/15 3/11 T3 40/47 21/40 16/39 8/29 4/22 2/21 NO 25/30 11/23 9/23 8/22 4/16 3/16 N1 45/50 22/39 15/37 6/26 4/21 2/16 Total 70/80 33/62 24/60 14/38 8/37 5/32 Conclusions: 1. EUS had a 77% T-stage accuracy. 2. EUS T-staging may predict long-term survival in pancreatic cancer. With a greater duration of follow-up for our cohort, we expect differences in survival between EUS T-staged pancreatic cancers to become significant. 3. EUS N-staging is not highly accurate (66% in this study), and does not predict long-term survival in this cohort of T-2 and T-3 lesions. 4. A substantial subset of patients (16%) live beyond 1.5 years after the diagnosis of pancreatic cancer regardless of whether a Whipple resection was performed.

AB - Endoscopic ultrasound (EUS) has been shown to be the most accurate imaging modality for preoperative T- and N-staging in pancreatic cancer. Pancreatic cancer (PanCa) often presents at an advanced stage, but a subset of patients may be cured by surgery. We prospectively followed patients after EUS for PanCa staging to determine the utility of EUS in predicting survival. Methods: 150 consecutive patients who underwent EUS (Olympus GF-UM20) for PanCa over a 42 month period were reviewed. Survival data was obtained on 93 patients. Results: All patients with T1 lesions (13) were alive at the time of this study. Results for all other lesions are presented below. For those with complete surgical pathologic staging, EUS had a 76% T-stage accuracy and a 66% N-stage accuracy. There was a trend towards improved survival for T2 versus T3 lesions at 15 months (27% for T2, 18% for T3) and 18 months (27% for T2, 9.5% for T3) (p<0.18). There was no trend towards improved survival for NO versus N1 lesions nor for those who underwent Whipple resection versus those who did not. Survival in months by EUS T- and N-staging # Alive 3 mo 6 mo 9 mo 12 mo 15 mo 18 mo T2 30/34 12/22 8/21 6/19 4/15 3/11 T3 40/47 21/40 16/39 8/29 4/22 2/21 NO 25/30 11/23 9/23 8/22 4/16 3/16 N1 45/50 22/39 15/37 6/26 4/21 2/16 Total 70/80 33/62 24/60 14/38 8/37 5/32 Conclusions: 1. EUS had a 77% T-stage accuracy. 2. EUS T-staging may predict long-term survival in pancreatic cancer. With a greater duration of follow-up for our cohort, we expect differences in survival between EUS T-staged pancreatic cancers to become significant. 3. EUS N-staging is not highly accurate (66% in this study), and does not predict long-term survival in this cohort of T-2 and T-3 lesions. 4. A substantial subset of patients (16%) live beyond 1.5 years after the diagnosis of pancreatic cancer regardless of whether a Whipple resection was performed.

UR - http://www.scopus.com/inward/record.url?scp=33748953577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748953577&partnerID=8YFLogxK

M3 - Article

VL - 45

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 4

ER -